Skip to main content

Fever Pitch (7.15.2022)

Jul 15, 2022 7:41 am

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on

  1. Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns).

  2. MTX + Pegloticase Combo FDA Approved Horizon has announced that the FDA has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.

  3. N.Zealand adult registry of ~1million without CV disease, amongst whom 32K had gout. Having gout increased risk of CV events in women (adj HR 1.34;1.23-1.45) and men (1.18). CV risk in men was increased if not on ULT & not at target (~15%)

  4. Should Physical exercise be recommended in dermatomyositis and polymyositis: a systematic review of 19 studies and 298 patients showed significant improvements in strength & aerobic capacity without change in CK levels or exacerbations

  5. 1 yr success of knee arthroplasty was drawn frm 20 studies (11 317 pts, 37 factors) suggests higher BMI was correlated w/ worse physical function. Physical function & OA severity assoc. w/ better function post-TKA

  6. Viscosupplementation Ineffective in Knee Osteoarthritis

  7. French registry of IBD due to IL-17 inhib revealed 32 pts- risk of new IBD was low & decreased 2016 to 2019, w/ good outcome in 24/31. IBD more common w/ AS (27) vs PsO (4), IBD onse after 4 (1.5–7.5) mos; all cases w/ secukinumab

  8. SELECT-AXIS 1 trial of upadacitinib in active #AS with an inadequate resp to prior biologic - pivotal phase 2/3 RCT of 420 AS pts (Dz dur 7.7 yrs; 83% B27+) showed better ASAS40 at wk 14 w/ UPA vs PBO (45% vs 18%; P<0.0001) #EULAR2022 POS0306

  9. 10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement.

  10. CDC: Immunocompromised account for 12.2% of all COVID-19 hospitalizations, with an increased risk of ICU (aOR=1.26) and death (aOR = 1.34), even if vaccinated (aOR 1.40; aOR = 1.87). In immunocompromised, death rate was not affected by vaccination.

  11. Worldwide metanalysis of FUO shows most common infections to be Mycobacterium tuberculosis (34%), brucellosis (10%), endocarditis (7.5%), abscesses (7%), herpesvirus (CMV,EBV 7%), pneumonia (6%), URI (6%), enteric fever (5%)

  12. FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts

  13. About 1 in 7 systemic JIA are "refractory" to standard Rx. Could the definition be active systemic or arthritic disease, despite IL-1 or IL-6 inhibitors? It could also include pts developing MAS, ILD or amyloidosis. Still, there are many Rx options.

  14. Guidelines for MAS complicating Systemic JIA: Dx is based on: - Fever in sJIA with ^ ferritin > 684, plus - Any 2 of these: elevated PLTs, AST, Triglycerides or low Fibrinogen

  15. Single center comparison of MAS (n 18) to malignancy related mHLH (n = 16). Notable differences seen in platelet (lower in mHLH 29k v 50K), soluble IL-2R (6814 vs 27972), but more hepatomegaly (25% v 0). Less mortality with MAS (22 v 44%, p 0.18)

  16. Cyclic GMP–AMP synthase (cGAS) engages stimulator of interferon genes (STING) to trigger inflammatory cytokines & type I interferons. cGAS–STING activation by genomic or mitochondrial self DNA implicated in autoinflammatory & autoimmune dz  mitochondrial DNA can drive SLE by PMN uptake, NETs, activation of STING & type-I IFN. Maybe same for Autoinflammatory responses were oxidized mtDNA provokes cGAS-STING, binding cytosolic NLRP3, triggering inflammasome activity.

  17. IL-18, Iike IL-1, is a produced by activation of the inflammasome. IL-18 is a potential bioimarker for #AOSD, closely linked to Dz activity & could be a Tx target, either as IL-18 binding protein (Tadekinig alfa) or mAb against IL-18 (phase 1b)

  18. MRP8/14 as a Biomarker in Systemic Juvenile Idiopathic Arthritis 


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has received compensation as an advisor or consultant on this subject